VKTX Stock Analysis: Buy, Sell, or Hold?
VKTX - Viking Therapeutics, Inc
$31.47
-1.05 (-3.23%)
▼
5d:
-3.32%
30d:
-7.0%
90d:
-15.36%
BUY
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: Apr 22, 2026
22d
Smart Money Accumulation
VKTX is down 8.7% this week, but smart money is accumulating calls. Top strike: $40 2026-05-15 with 4,226 OI. Call ratio: 87% View Scanner →
Strength: 8.0/10
Get Alerted When VKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VKTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VKTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VKTX is currently trading at $31.47, which is considered fair relative to its 30-day fair value range of $31.67 to $34.81.
Technical Outlook: Technically, VKTX is in a downtrend. The price is currently testing key support at $31.49. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $92.72 (+185.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VKTX is in a downtrend. The price is currently testing key support at $31.49. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $92.72 (+185.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$31.67 -
$34.81
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 185.1% below Wall St target ($92.72)
Fair Price Analysis
30-Day Fair Range
$31.67 -
$34.81
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$31.49
Resistance Level
$36.63
Current Trend
Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.29
Wall Street Target
$92.72
(+185.1%)
Share & Embed Analysis
Last updated: March 30, 2026 9:55 AM ET
Data refreshes hourly during market hours. Next update: 10:55 AM
Data refreshes hourly during market hours. Next update: 10:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VKTX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Neil William Aubuchon
BUY
4475 shares
2026-03-10
Brian Lian
SELL
233409 shares
2026-01-05
Greg Zante
SELL
57661 shares
2026-01-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 47 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 49 HOLD |
